GATEWAY BIOTECHNOLOGY, INC.
Electrical calibration device and machine learning software for auditory brainstem response (ABR) and electrocochleography (ECochG) measurement to diagnose cochlear synaptopathy
- Sector
- Medtech
- Headquarters
- Saint Louis, MO
- Latest Form D
- $633K, Jun 2025
- Total capital
- $7.4M
- Federal grants
- $6.7M
- 14 awards · 2016–2024
- Rank in peer group#96 of 538
- Private capital raised
- $633K
- 1 Form D · last Jun 2025
- 17 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 10 pending · first 2019
- Rank in peer group#237 of 538
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$633K
- Federal grantHealth and Human S · Phase II · Developing a clinical diagnostic tool for age-related cochlear synaptopathy.$483K
- Federal grantDefense · Phase II · GW-TT2, a New Drug Product for Tinnitus.$1.3M
- Federal grantHealth and Human S · Phase II · Developing a clinical diagnostic tool for age-related cochlear synaptopathy.$474K
- Federal grantHealth and Human S · Phase II · Developing a clinical diagnostic tool for age-related cochlear synaptopathy.$556K
- Federal grantHealth and Human S · Phase II · Targeting multiple signaling pathways for tinnitus prevention and treatment$1.2M
- Federal grantHealth and Human S · Phase II · Targeting multiple signaling pathways for tinnitus prevention and treatment$973K
Show 8 earlier federal awards
- Federal grantHealth and Human S · Phase I · An unique patient population for clinical trials against noise-induced hearing loss$100K
- Federal grantHealth and Human S · Phase I · Developing a Nutraceutical Product against Ototoxicity$205K
- Federal grantHealth and Human S · Phase I · An unique patient population for clinical trials against noise-induced hearing loss$325K
- Federal grantHealth and Human S · Phase I · Developing a new AAV-based tool for targeted gene therapy against hearing loss$225K
- Federal grantHealth and Human S · Phase I · Developing a Nutraceutical Product against Noise Induce Hearing Loss$225K
- Federal grantHealth and Human S · Phase I · Developing a Nutraceutical Product against Noise-Induce Hearing Loss$225K
- Federal grantHealth and Human S · Phase I · Develop a new cisplatin-based drug combination with reduced ototoxicity$225K
- Federal grantHealth and Human S · Phase I · Preclinical Testing of Tetrandrine against Noise-Induce Hearing Loss$225K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
109months
from GATEWAY BIOTECHNOLOGY, INC.’s first federal award to its first private round.
- First federal award · May 2016
- Health and Human S · $225K
- First Form D · Jun 2025
- $633K · 1st Form D
- Awards before first raise
- 14 awards
An association in public records, not a cause or a prediction.
Standing among 538 peers
Line = medianMedtech · Device
- Federal grants#96 · top 18%
- Granted patents#237 · top 44%
- Linked publications#36 · top 7%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Jianxin BaoResearcherExecutive OfficerLinked by 1 patent · $3.7M in grants as PI
- Philip PerezDirectorNamed in SEC Form D filings
- Richard CholeDirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 11- GrantedMethods And Compositions For Treating Hearing DisordersUSPTOUS 10,434,097
- PendingMethods And Compositions For The Treatment Of Hearing DisordersUSPTOApplication 19145083
- PendingCombination Therapies For Treatment Of Hearing DisordersUSPTOApplication 19138957
Show all 11 patent records
- Methods And Compositions For Treating Hearing DisordersOct 8, 2019 · US 10,434,097Granted
- Methods And Compositions For The Treatment Of Hearing DisordersApplication 19145083Pending
- Combination Therapies For Treatment Of Hearing DisordersApplication 19138957Pending
- Chemogenetics-based Therapy For Neurological DisordersApplication PCTUS2024017872Pending
- Combination Therapies For Treatment Of Hearing DisordersApplication PCTUS2024010520Pending
- Chemogenetics-based Therapy For Neurological DisordersApplication 63487842Pending
- Methods And Compositions For The Treatment Of Hearing DisordersApplication 63478883Pending
- Combination Therapies For Treatment Of Hearing DisordersApplication 63478889Pending
- Methods And Compositions For Treating Hearing DisordersApplication 15265302Pending
- Chemogenetics-based Therapy For Neurological DisordersApplication 19159503Pending
- Methods And Compositions For Treating Hearing DisordersApplication 62218483Pending
Recent research by its founders
- Numerical Analysis of the Pullout Bearing Characteristics of Artificial Excavated Piles with Post-Grouting after Prefabricated Retaining Walls20251 cites
- Developing a Calibration Method to Minimize Variability in Auditory Evoked Potentials20250 cites
- Field Tests of the Horizontal Freezing Method for Shield Tunneling in Complex Sites20245 cites
Related companies, and why
- FAUXSEE INNOVATIONS LLCSimilar federal contract value in Medtech · null in contracts
- CELL IDX, INC.Similar federal contract value in Medtech · null in contracts
- PROTEAS BIOANALYTICS INC.Similar federal contract value in Medtech · null in contracts
- MicroStructure Imaging, Inc.Similar federal contract value in Medtech · null in contracts
- ENDOTHEIA INCSimilar federal contract value in Medtech · null in contracts
- GYNION, LLCSimilar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .